Acoustic Neuroma
14
1
3
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.1%
1 terminated out of 14 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (14)
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
Roy Adaptation Model Improves Mood and QOL After Giant Acoustic Neuroma
Maintaining Cochlear Patency After VIIIth Nerve Surgery
Study of Aspirin in Patients With Vestibular Schwannoma
Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma
Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
Evolution of Vestibular Function After Treatment of a Vestibular Schwannoma by Gamma-knife Radio-surgery
Auditory Nerve Test System During Vestibular Schwannoma Resection
Evaluating the Pre-Positioning Frame for Robotic Acoustic Neuroma Removal Surgery
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Acoustic Neuroma: Assessing the Quality of Life by the Scale PANQOL of Patients Operated or Supervised
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
RGD PET/MRI in Sporadic Vestibular Schwannoma